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Abstract
Background: There are several guidelines addressing the issues around the use of NSAIDs. However, none has
specifically addressed the upper versus lower gastrointestinal (GI) risk of COX-2 selective and non-selective
compounds nor the interaction at both the GI and cardiovascular (CV) level of either class of drugs with low-dose
aspirin. This Consensus paper aims to develop statements and guidance devoted to these specific issues through a
review of current evidence by a multidisciplinary group of experts.
Methods: A modified Delphi consensus process was adopted to determine the level of agreement with each
statement and to determine the level of agreement with the strength of evidence to be assigned to the statement.
Results: For patients with both low GI and CV risks, any non-selective NSAID (ns-NSAID) alone may be acceptable. For those
with low GI and high CV risk, naproxen may be preferred because of its potential lower CV risk compared with other
ns-NSAIDs or COX-2 selective inhibitors, but celecoxib at the lowest approved dose (200 mg once daily) may be acceptable.
In patients with high GI risk, if CV risk is low, a COX-2 selective inhibitor alone or ns-NSAID with a proton pump inhibitor
appears to offer similar protection from upper GI events. However, only celecoxib will reduce mucosal harm throughout the
entire GI tract. When both GI and CV risks are high, the optimal strategy is to avoid NSAID therapy, if at all possible.
Conclusions: Time is now ripe for offering patients with osteoarthritis the safest and most cost-effective
therapeutic option, thus preventing serious adverse events which could have important quality of life and
resource use implications.
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Background
Pain is a common reason for patients to visit their family
physician [1,2] and the numbers seeking treatment for
pain is anticipated to rise as the population ages and
chronic conditions, such as osteoarthritis (OA), increase.
In the United Kingdom (UK), annually, more than 17
million prescriptions are written for anti-inflammatory
and analgesic drugs [3]. In addition, over-the-counter an-
algesic (non-steroidal anti-inflammatory drugs (NSAIDs)
and paracetamol) use is substantial, with 44% of patients
consuming more than the recommended dosage on the
label [4]. Musculoskeletal pain is common and disabling,
especially in the elderly population, whose number and
proportion is estimated to double by 2030, compared to
the 2000 figure [5]. Prescribing pain medications within
this particular population requires the skill of a know-
ledgeable physician to navigate through the numerous
variables (e.g., physiologic changes, co-morbidities, and
co-therapies) that make the elderly a heterogeneous and
complex population to treat [6,7].
Over the last few years, professional organizations, in-
cluding the American College of Rheumatology [8], the
American Pain Society [9], and the European League
Against Rheumatism [10], have published treatment guide-
lines to assist clinicians in achieving effective pain manage-
ment. Safety is a core concern in all these guidelines,
especially for chronic conditions, such as OA, that re-
quire long-term treatment. Hence, there is a consensus
among recommendations that paracetamol (acetamino-
phen) should be the first-line analgesic agent due to its
favorable side effect and safety profile, despite several
meta-analyses having shown that it is less effective in
pain relief than anti-inflammatory drugs [11-14].
Besides being a less effective analgesic, paracetamol
may not be as safe as believed, both from a gastrointes-
tinal (GI) and cardiovascular (CV) perspective, not to
mention the well-known hepatotoxicity (especially at
doses higher than 3 g daily) [15]. Indeed, a nested case-
control study found that use of this compound (any dose)
is associated with a small but significant risk of upper GI
complications (relative risk [RR], 1.3; 95% confidence
interval [CI], 1.1–1.5) [16]. The RR was 3.6 (95% CI,
2.6–5.1) among paracetamol users of more than 2 g daily.
In addition, while women from the Nurses’ Health Study,
who reported occasional use of paracetamol, did not ex-
perience a significant increase in the risk of CV events,
those who reported a frequent (6–14 tablets/week) use
had a RR of 1.35 (95% CI, 1.14–1.59) [17]. Finally, regular
paracetamol use is associated with an increased risk of
hypertension both in women [18] and men [19]. More re-
cently, it was also shown that paracetamol, at doses of 3 g
daily, induces a significant increase in ambulatory blood
pressure in patients with coronary artery disease [20]. The
above findings are not surprising in the light of the recent
discovery that paracetamol is indeed a selective cyclooxy-
genase (COX)-2 inhibitor in man [21].
Although OA has long been considered a “wear and
tear” disease leading to loss of cartilage, progress in mo-
lecular biology in the 1990s has profoundly modified this
paradigm. The discovery that many soluble mediators,
such as cytokines or prostaglandins, can increase the pro-
duction of matrix metalloproteinases by chondrocytes, led
to the first steps of an “inflammatory” theory [22,23]. Re-
cent experimental data have shown that subchondral bone
may have a substantial role in the OA process, as a me-
chanical dampener, as well as a source of inflammatory
mediators implicated both in the OA pain process and in
the degradation of the cartilage deep layer [24]. Thus,
initially considered cartilage driven, OA, the prototypic
age-related disease [25], is much more complex than
previously thought and low-grade (local and systemic)
inflammation is the hallmark of this chronic and progres-
sing condition [24]. Thus, COX-2 selective or non-selective
NSAIDs (ns-NSAIDs), which display both analgesic and
anti-inflammatory properties, represent a pathophysio-
logically sound approach.
NSAIDs are very effective drugs [8-10,26,27], but their
use is associated with a broad spectrum of adverse reac-
tions involving the liver, kidney, CV system, skin, and
gut [28]. GI side effects are the most common and cover
a wide clinical spectrum ranging from dyspepsia, heart-
burn, and abdominal discomfort to more serious events
such as peptic ulcer with life-threatening complications
of bleeding and perforation [29,30]. The dilemma for the
physician prescribing NSAIDs is, therefore, to maintain
the anti-inflammatory and analgesic benefits while redu-
cing or preventing their untoward GI effects.
The use of all medications increases with age and the
elderly are at increased risk of adverse drug reactions.
The occurrence of GI complications depends on the
presence and number of risk factors, and age is the most
frequent and relevant of these. Thus, patients at upper
GI risk should have preventative strategies in place, in-
cluding the use of the lowest effective dose of NSAID, co-
therapy with a gastroprotective drug, or the use of a
COX-2 selective agent [31,32]. However, eradication of as-
sociated Helicobacter pylori (H. pylori) infection has been
shown to be beneficial when starting treatment with
NSAIDs or aspirin, especially in the presence of an ulcer
history [33-35] and was recommended by the latest Maas-
tricht IV/Florence European Consensus report [36]. In
contrast, eradication appears not to be useful in patients
already under long-term NSAID treatment, which is the
most common picture in clinical practice [37]. The best
strategy to prevent lower GI complications has yet to be
defined.
It is increasingly recognized that the small bowel, like
the stomach, is a site for NSAID-associated mucosal
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lesions, giving rise to NSAID-enteropathy [38]. Over
the last 10 years, there has been a decreasing trend in
NSAID-induced symptomatic GI events in rheumatic
patients [39] and, in line with that, in hospitalizations
due to upper GI complications, while lower GI compli-
cations showed an apparent increasing trend [40-43]. In
addition, the clinical impact and severity of lower GI
events have actually been greater than those in the up-
per GI tract [41]. Recent evidence has also shown that
proton pump inhibitors (PPIs) are unable to prevent
NSAID-associated intestinal damage and that some
COX-2 selective inhibitors display a better intestinal
tolerability compared to traditional (i.e. non selective)
NSAIDs, with or without acid inhibition [30,44].
During the last few years, great attention has been
focused on the adverse CV effects of COX-2 selective
NSAIDs, which prompted a re-evaluation of the CV and
global safety profile of traditional anti-inflammatory
drugs. The increased CV risk of COX-2 selective inhibi-
tors has been well documented in randomized con-
trolled trials (RCTs) and observational studies. While
this risk may be different according to dose and patient
baseline CV clinical conditions, more recent evidence
suggests that at least some, if not all, ns-NSAIDs may
also increase that risk [45-48]. The reno-vascular effects
of NSAIDs are also well known. Current evidence sug-
gests that ns-NSAIDs and COX-2 selective NSAIDs
have a similar incidence of these adverse effects, but
with molecule-specific quantitative differences between
the various drugs [49].
Although the two processes can be separated at the
cellular, tissue, and clinical levels, aging and the deve-
lopment of OA are closely linked [50]. CV risk factors
also increase with age [51] and the presence of CV co-
morbidity is rather high (up to 44%) in patients with OA
[52-54]; out of a large (>17,000 subjects) population of
OA patients, 21.4% were low-dose aspirin users [54].
The presence of CV comorbidities and concomitant aspirin
use influence NSAID selection among rheumatologists
[54,55]; however, NSAID prescribing was not always
appropriate or in accordance with current guidelines or
recommendations by regulatory agencies [54].
There are several guidelines and expert recommenda-
tions addressing the issues around the use of NSAIDs
[8,32,56-70]. However, none has specifically addressed
the upper versus lower GI risk of COX-2 selective and
non-selective compounds or the interaction at both the
GI and CV level of either class of drugs with low-dose
aspirin. To this end, a multidisciplinary group of experts
convened to review current evidence, with the aim of
developing statements and guidance devoted to these
specific issues, to help clinicians make evidence-based
decisions when selecting anti-inflammatory agents for
the individual patient.
Materials and methods
Clinically relevant consensus statements relating to
NSAID use were developed according to generally ac-
cepted standards [71], following a methodology similar
to the one adopted by the Canadian consensus group [68].
In 2011, a series of meetings were held in Amsterdam
(the Netherlands) and Treviso (Italy) with a multidiscip-
linary group of experts, during which key themes around
CV and GI risk were identified, current data reviewed,
and knowledge gaps recognized. The aim of the meet-
ings was two-fold – i) to identify and address ongoing
issues around CV and GI risk associated with NSAIDs,
which leave primary care physicians uncertain about
how to prescribe these drugs in patients with OA; and
ii) to develop practical evidence-based clinical guidance
on the appropriate use of NSAID therapy.
Following each meeting, statements to help inform
recommendations for the management of pain in pa-
tients with OA were drafted. A core group of expert
statement leaders (Frank Buttgereit, non-voting Chair
of the Consensus Group, Richard H Hunt, Carmelo
Scarpignato) gathered supporting evidence and refined
the statements following review by and feedback from
the wider expert group (Corrado Blandizzi, Ernest Choy,
Mart van der Laar, Angel Lanas, Willem F Lems, Andrew
Moore). This culminated in the Expert Summit meeting
(Amsterdam, November 15–16, 2011), during which
34 experts met, discussed the evidence, and voted on
nine clinical statements around the efficacy of NSAIDs
and NSAID-associated CV and GI risks. Consensus was
reached on all nine statements (i.e., ≥75% agreement,
see below).
Membership of the consensus group
An organizing committee selected a non-voting Chair
and an international, multidisciplinary group of 34 vot-
ing physicians and evidence-based medicine experts
(Additional file 1). Non-voting observers included repre-
sentatives from the Lucid Group (who provided the logis-
tic support for the meeting as well as editorial assistance)
and from the pharmaceutical industry (Additional file 1).
Representatives from these groups did not participate in
any consensus discussions or in the voting.
Nature and extent of background preparation
Each statement leader addressed a specific topic and
made their own selection of primary references and sys-
tematic reviews by searching MEDLINE, EMBASE, and
CINAHL databases (from 1990 to October 2011) as well
as the proceedings of the major digestive and rheuma-
tology meetings. The writing and references provided by
each statement leader were circulated among all the
members of the expert group, who sent their written com-
ments prior to the meeting. In reviewing the statements
Scarpignato et al. BMC Medicine  (2015) 13:55 Page 3 of 22
and evidence, experts were encouraged to suggest amend-
ments to the wording of the statements, as well as ad-
ditions or deletions to the list of references, as they felt
appropriate. In either case, they were asked to also state
the rational for their suggested amendments.
Once all the feedback was collated, for each statement, a
restricted (n = 1 to 3) number of experts (designated as
statement group members) provided – during a telecon-
ference – their feedback and suggestions for improvement
and/or change of both the wording of each statement and
the supporting evidence, taking into account the views of
the wider expert group. This revised list of nine statements
was brought for discussion at the Consensus meeting.
Modified Delphi consensus process
The revised (preliminary) statements were circulated
electronically for review before the meeting. A summary
of the evidence was presented by each statement leader
during the meeting [72].
At the end of each presentation, an in-depth discussion,
driven by the Chair, was held with two objectives, namely
i) to clarify the meaning of the statement or to reduce any
ambiguity and ii) to clarify any queries regarding the evi-
dence. On some occasions this resulted in further modifi-
cation of the statement. The final statement was then
voted on in two parts. The first vote was to determine the
level of agreement with the statement itself and the sec-
ond to determine the level of agreement with the strength
of evidence to be assigned to the statement. All voting at
the meeting was conducted using keypads to ensure that
the process was anonymous. Experts were asked to indi-
cate a level of agreement with the statement on a scale of
‘a’ to ‘f ’, ranging from strongly agree to strongly disagree.
Statements were accepted when more than 75% of partici-
pants voted ‘a’, ‘b’, or ‘c’ (agree strongly, agree moderately,
or agree mildly). The strength of evidence was assessed as
suggested by the GRADE working group (Table 1) and
each statement was assigned a grade to indicate the qua-
lity of evidence [73]. Evidence grades were recorded as
voted for by the experts.
General meeting organization
A 2-day consensus conference was held on November
15 to 16, 2011, in accordance with generally accepted
Table 1 Grading of the quality of the evidence based on the GRADE system
Nature of evidence Study design Study execution Consistency Directness of evidence
A Pairwise meta-analysis of comparative randomized
controlled trials (RCTs) (for interventions)
No important flaws Consistent Direct or strong indirect
RCTs (for interventions)
Non-randomized studies (for diagnosis and prognosis)
B Meta-analysis of RCTs or RCTs (for interventions) Important flaw < OR > Inconsistent < OR >Weak indirect
Non-randomized studies (for diagnosis or prognosis) Important flaw < OR > Inconsistent < OR >Weak indirect
Non-randomized controlled studies (for interventions) No important flaws consistent direct < OR > Strong indirect
C Non-randomized controlled studies (for interventions) Important flaw < OR > Inconsistent < OR >Weak indirect
Meta-analyses or RCTs with a combination of important flaws AND inconsistency AND/OR indirect evidence
D Other evidence (not expert opinion)
E Expert opinion
Exceptions that can alter the quality of grading
Sparse data (few events); use of data not in its initial randomization or apparent publication bias can lower the quality; a very strong association can
raise the quality
Coding notes
Important flaws occur when the highest standards of research that could be achieved by a study are not applied
Consistency occurs at two levels – design: consistent methods, patients, outcomes; and statistical: a test of homogeneity of a summary estimate
when the level of design consistency is acceptable and meta-analysis appropriate
Directness – direct evidence: relevant patient benefits and harms are measured in studies; strong indirect: the surrogate endpoint is strongly related
to desirable endpoints, or direct evidence is available for a sufficiently related patient group; weak indirect: the relationship between the study
outcomes and patient benefits or harms is insufficient
Summary of quality of evidence
A. High quality of evidence – future evidence is unlikely to change confidence in the estimate of effect
B. Moderate quality of evidence – future evidence is likely to have an impact on the confidence of the estimate of effect and may change that estimate
C. Poor quality evidence – future evidence is very likely to have an impact on the confidence of the estimate of effect and is likely to change that estimate
D. and E. Very poor quality evidence – Any estimate of effect is very uncertain
Developed from Lomas J, 1991 [71].
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standards for the development of clinical practice guide-
lines [74]. Statements of conflicts of interest were ob-
tained from all voting participants [75].
Lucid Group (London, UK) managed all the organiza-
tion, the audio recording and the electronic voting sys-
tem. The Consensus conference and the previous expert
meetings were supported through an unrestricted educa-
tional grant from Pfizer Europe, who entrusted Lucid
with the management of the whole process.
Preparation of the consensus paper
A core working group of experts drafted the manuscript
(CS, AL, CB, RH), which was then reviewed by all the
statements leaders and the authors, who all approved
the final draft.
Results
Presentation of the statements
Each statement is followed by the ‘grade’ of supporting
evidence and the results of the two votes: i) agreement
with the statement and ii) agreement with the grade of
evidence followed by a brief summary. A consensus was
considered reached when more than 75% of participants
voted a, b, or c (agree strongly, agree moderately, or
agree mildly).
NSAIDs: efficacy in OA and impact on quality of life (QoL)
Statement 1: OA impacts quality and quantity of life;
it should therefore be treated appropriately. Level of
Agreement: Strong Agreement (vote statement: a, 48.5%;
b, 36.4%; c, 12.1%; d, 3%). Level of Evidence: B (vote
grade: A, 42.4%; B, 48.5%; C, 9.1%).
Pain strongly and negatively impacts QoL, with in-
creasing evidence that it may also impact quantity of life.
Chronic pain interferes with the domains of physical and
social functioning, emotional and mental health, energy,
vitality, and general health [76]. In addition, it has been
shown to be indirectly associated with a reduced cumu-
lative survival due to CV and respiratory causes [77].
QoL is adversely impacted by OA and this has been
shown in large, comprehensive, cross-sectional, or longi-
tudinal studies [78], and this is supported by many other
studies confirming the same conclusions. OA patients
suffer a spectrum of symptoms, which impair normal
daily functions including sleeping, walking, climbing
stairs, opening containers, preparing food, or self-caring
to variable extents [78]. There is evidence that chronic
musculoskeletal disorders, including OA, have an overall
greater adverse impact on QoL than other chronic dis-
eases such as CV, respiratory, cerebrovascular, and neu-
rologic disorders, GI diseases, and cancer [79].
Three large, comprehensive, longitudinal studies con-
firm the effect of OA on longevity [77,80-82]. Reduced
physical function, especially walking disability, is a major
risk factor for mortality in OA patients [81]. Thus, phys-
ical activity is good for health [80]. The potential impact
of disability on longevity has also been demonstrated in
other musculoskeletal inflammatory conditions. In a co-
hort of patients with ankylosing spondylitis followed for
up to 33 years, the highest mortality was associated with
greater disability and with non-use of NSAIDs [83].
Large observational studies and analyses of RCTs or
pooled data confirm the important benefits of treating
OA [84-86]. Treatment of OA improves physical per-
formance and is beneficial to several domains of arthritis
function, including pain, stiffness, function, and global
ratings of performance. In addition, it improves the
quality of sleep [87-89].
Statement 2: Many OA patients requiring NSAID
therapy are not being treated appropriately according to
their GI risk profile. Level of Agreement: Strong Agree-
ment (vote statement: a, 75.0%; b, 21.9%; c, 3.1%). Level
of Evidence: A (vote grade: A, 68.8%; B, 28.1%; C, 3.1%).
There is convincing evidence supporting the use of
gastroprotective strategies in at-risk patients treated with
NSAIDs, which has been adopted by different guidelines
worldwide [90,91]. Patients at increased GI risk can be
identified by a history of complicated or uncomplicated
ulcers, advancing age (patients older than 60 to 65 years,
depending on guidelines), use of concomitant medication
(especially low-dose aspirin or anticoagulants), and the
presence of H. pylori infection [61]. NSAID-treated OA
patients with risk factors can be exposed to inappropriate
therapy as a result of not receiving gastroprotective ther-
apy, not being adherent to the prescribed therapy, or get-
ting non-indicated prevention strategies. Diverse studies
with different methodological approaches in different co-
horts of patients have reported important findings in this
regard. Very low rates of prescription of gastroprotective
therapies according to national or international guidelines
have been reported, although these rates have increased
progressively [92-96]. In the Netherlands, correct pre-
scription rose from 6.9% in 1996 to 39.4% in 2006 in high-
risk NSAID users, whereas over-prescription rose from
2.9% to 12.3% [97].
Similar rates were reported in a cross-sectional study of
patients prescribed NSAIDs in the United States of Amer-
ica, where only 27.2% of high-risk patients were prescribed
a gastroprotective compound according to guidelines.
Among patients from VA hospitals with at least two risk
factors, adherence to guidelines was 39.7%; among those
with three risk factors, adherence was 41.8%. The likeli-
hood of adherence was further decreased if they were pre-
scribed NSAIDs for ≥90 days [98]. Review of medical
charts in one large cross-sectional study (n = 17,105) of
OA patients found that, in over half of the population ex-
amined, NSAID prescriptions did not follow guidelines.
Specific areas, where the recommendations were not
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followed or were overlooked, were in patients with both
high GI and CV history (74% inappropriate) and in
those with a high GI risk alone (49% inappropriate).
However, other recommendations were followed. The
study showed high rates of PPI co-prescription with ns-
NSAIDs in patients with increased GI risk. However,
half of patients with low GI risk and no CV history were
still treated with ns-NSAIDs plus a PPI or a COX-2 selec-
tive NSAID, contrary to current guidelines [54]. A re-
cent study in Canada has reported that concordance with
guideline recommendations increased for celecoxib and
decreased for ns-NSAIDs after rofecoxib withdrawal,
whereas co-prescription of gastroprotective agents with
ns-NSAIDs remained suboptimal, with only 45.6% of
at-risk patients receiving these drugs [99].
Adherence by patients to the prescribed drug is an-
other problem. Early reports showed that over one third
of patients did not take the gastroprotective agents as
prescribed [94]. More recent studies reported similar or
better rates for prescription lasting <3 months [100,101],
but others reported much lower adherence rates [92,93].
Appropriate prescription and optimal adherence are
important for NSAID users; evidence indicates that pa-
tients with risk factors who do not receive or follow ap-
propriate prevention strategies have an increased risk
of GI complications [100,102]. A recent study involving
three European databases found that, among NSAID
treated patients with low adherence (<20% of the time
with gastroprotection), the odds ratio (OR) was 2.39 (95%
CI, 1.66–3.44) for all upper GI events and 1.89 (95% CI,
1.09–3.28) for upper GI bleeding alone when compared to
patients who had high levels of adherence (>80% of the
time on NSAIDs with gastroprotection) [96]. This in-
creased risk among patients with low adherence was also
found in high-risk patients who received a COX-2 selective
inhibitor alone whereas guidelines recommend combin-
ation of a COX-2 selective inhibitor with a PPI [103].
Statement 3a: The efficacy of ns-NSAIDs and COX-2
selective inhibitors in pain is comparable in patients with
OA. Level of Agreement: Strong Agreement (vote state-
ment: a, 87.5%; b, 12.5%). Level of Evidence: A (vote
grade: A, 87.5%; B, 9.4%; C, 3.1%).
Statement 3b: The efficacy of ns-NSAIDs and COX-2
selective inhibitors in pain is comparable in patients
with rheumatoid arthritis (RA). Level of Agreement:
Strong Agreement (vote statement: a, 84.4%; b, 9.4%; c,
6.3%). Level of Evidence: A (vote grade: A, 87.5%; B,
9.4%; C, 3.1%).
The discussion about whether ns-NSAIDs or COX-2
selective inhibitors should be preferred in patients with
RA or OA is usually dominated by the possible GI and
CV events. Although these adverse effects may have dra-
matic manifestations, they occur only in a minority of pa-
tients. Other issues, like tolerability, adherence to therapy,
and cost/price of the drug, may also play a role. However,
and perhaps of primary importance, the analgesic and
anti-inflammatory effect is crucial for patients suffering
from pain due to RA or OA.
In at least five high quality RCTs, a comparable ef-
fectiveness has been shown:
1. Different doses of celecoxib (100, 200, and 400 mg/
day) were all comparable to naproxen (1,000 mg/
day), and superior to placebo, in a 12-week study in
patients with RA [104];
2. Celecoxib (200 mg/day) was as effective as
diclofenac (150 mg/day) in the long-term
management of RA [105];
3. Etoricoxib (60 to 90 mg/day) was as effective
as diclofenac (150 mg/day), in RA and OA
patients [106];
4. Celecoxib (200 mg/day) was as effective as naproxen
1,000 mg/day in patients with knee OA [107];
5. In the Celecoxib versus Omeprazole and Diclofenac
in Patients with Osteoarthritis and Rheumatoid
arthritis (CONDOR) study, no difference in
effectiveness was found between celecoxib
(400 mg/day) and diclofenac (150 mg/day) in RA
and OA patients [108].
6. In other studies, rofecoxib was as effective as
naproxen [109], and lumiracoxib as diclofenac [110].
However, neither rofecoxib nor lumiracoxib are now
available. In fact, all these studies clearly show that
ns-NSAIDs and COX-2 selective inhibitors have
comparable efficacy, apparent in functioning and
disability, as well as in pain.
It is worth emphasizing that, although these drugs seem
to have – as a class and at a population-based level – a
comparable effect, individual treatment responses may be
variable and dose-dependent. Thus, in daily practice the
choice between ns-NSAIDs and COX-2 selective inhi-
bitors will depend on the CV and GI risk profile, drug-
tolerability, clinical experience of the physician with the
given drug, cost/price, and pharmaco-economic conside-
rations, as well as individual patient response.
GI risks of NSAIDs
Statement 4: NSAID use is associated with increased
risk of adverse events throughout the entire GI tract;
this is associated with substantial mortality. Level of
Agreement: Strong Agreement (vote statement: a, 75.0%;
b, 21.9%; c, 3.1%). Level of Evidence: A (vote grade: A,
87.5%; B, 12.5%).
The GI adverse effects of NSAIDs have been well
documented in several studies [111-115], meta-analyses
[116-118], and Cochrane reviews [119]. The majority of
these studies have reported adverse events in the upper
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GI tract. The meta-analysis by Ofman et al. [118], which
reviewed severe upper GI complications in almost 800,000
patients taking oral NSAIDs for at least 4 days, showed
an OR of 5.36 (95% CI, 1.79–16.1) from 16 RCTs (ver-
sus placebo), RR of 2.7 (95% CI, 2.1–3.5) from 9 cohort
studies, and OR of 3.0 (95% CI, 2.5–3.7) from 23 case
control studies for severe upper GI complications,
which included perforations, clinically relevant ulcers,
and bleeding [118].
Similarly, low-dose (≤325 mg daily) aspirin is asso-
ciated with major upper GI bleeding: the RR was 2.1
(95% CI, 1.6–2.7) in the meta-analysis by McQuaid and
Laine [120] and 2.6 (95% CI, 2.2–2.9) in the large Danish
cohort study, carried out by Sørensen et al. [121]. Lanas
et al. [122] recently reported an OR of 1.55 (95% CI,
1.27–1.90) and found that PPI use reduced the risk of
major GI bleeding (OR, 0.34; 95% CI, 0.21–0.57).
A predictable and consistent GI blood loss has been
shown in healthy volunteers taking ibuprofen (800 mg
t.i.d.) [115]. Bleeding was observed in 27/31 subjects
(87%) and averaged 4.5 to 5.0 mL/day (SD, 12; range,
0–65 mL/day) with an onset of 3 to 5 days after starting
the drug [115].
In the recent CONDOR study, a large, prospective
RCT (n = 4,400), the cumulative proportion of patients
with adjudicated, clinically significant events throughout
the GI tract was significantly greater in those patients
taking diclofenac in combination with omeprazole, des-
pite the partial protection provided by the PPI in the
upper GI tract, than in patients taking celecoxib [108].
The effect of NSAID use on mortality has been less
well studied and a figure of 16,500 deaths in the US has
been widely quoted since the original estimate was pub-
lished [123]. However, in a more recent report of results
from two concurrent Spanish studies [114], the inci-
dence of hospital admission due to major GI events of
the entire (upper and lower) GI tract was 121.9 events/
100,000 person/years and admissions for upper GI com-
plications were six-fold higher than for lower GI tract
events. Mortality rates attributed to NSAIDs/low-dose
aspirin use were substantial, at 21.0 and 24.8 cases/
million people, respectively, and up to one-third of all
NSAID/aspirin deaths could be attributed to low-dose
aspirin use. Mortality rates associated with either major
upper or lower GI events were similar, 5.57% (95% CI,
4.9–6.7) and 5.62% (95% CI, 4.8–6.8), respectively. How-
ever, upper GI events were more frequent. Moreover,
three further studies reported mortality figures, which
range from 3.8 to 11% in patients with peptic ulcer
bleeding associated with NSAID use [124-126]. Fur-
thermore, while the adverse events associated with
NSAID use can lead to mortality, this could be due to
associated causes other than GI adverse events (e.g.,
CV events) [127].
Statement 5: NSAID-induced adverse events in the
lower GI tract are not prevented by PPIs. Level of Agree-
ment: Strong Agreement (vote statement: a, 75.0%; b,
18.8%; c, 3.1%; d, 3.1%). Level of Evidence: B (vote grade:
A, 43.8%; B, 56.3%).
While it is clear that PPIs reduce the development of
peptic ulcer and ulcer complications in patients taking
NSAIDs and/or aspirin, their beneficial effect, which is
related to their antisecretory activity [128], is not ex-
pected beyond the duodenum [30]. The appreciation
that NSAID-associated GI damage does extend beyond
the duodenum dates back to the early 90’s, when a few
observational studies and the first large RCT prevention
study (i.e., the Misoprostol Ulcer Complication Out-
comes Safety Assessment (MUCOSA) trial) were pub-
lished [129]. In the more recent Vioxx™ Gastrointestinal
Outcomes Research (VIGOR) trial, more than 40% of
the NSAID-related events occurred in the lower (i.e.,
small bowel and colon) GI tract [130]. A systematic re-
view [131] of 47 studies (18 randomized, 14 case-control,
8 cohort, and 7 before/after studies) found that patients
taking ns-NSAIDs had significantly more adverse effects
versus no NSAID use in 20/22 lower GI integrity studies
(dealing with permeability, inflammation, and microscopic
lesions), 5/7 visualization studies, 7/11 bleeding studies
(OR, 1.9–18.4 in case-control studies), 2/2 perforation
studies (OR, 2.5–8.1), and 5/7 diverticular disease studies
(OR, 1.5–11.2). As reported in the Spanish studies (de-
scribed under Statement 4), over the past decade there
has been a progressive change in the overall picture of GI
events leading to hospitalization, with a clear decreasing
trend in upper GI events and a slight but significant in-
crease in lower GI events [41].
The availability of video capsule endoscopy has allowed
a precise quantification of the incidence and characteriza-
tion of small intestinal damage. Indeed, available studies
[132,133] show that about 75% of NSAID users display in-
testinal mucosal injury, with most denuded areas identi-
fied in the proximal part of the small bowel and all ulcers
identified in the distal part [134].
In healthy volunteers [133,135,136] and patients [132],
omeprazole did not prevent NSAID-associated intestinal
damage, evaluated by video capsule and/or fecal calpro-
tectin measurement. The failure of PPIs to protect the
small bowel is due to the fact that NSAID-enteropathy is
not a pH-dependent phenomenon [30]. Indeed, although
inhibition of mucosal prostaglandin synthesis with NSAID
use occurs along the entire digestive tract, there are sig-
nificant differences between the distal and proximal GI
tract in the concurrence of other pathogenic factors that
may add to mucosal damage. Among the most evident are
the absence of acid (which plays a pivotal role in upper GI
damage) and the presence of bacteria and bile in the intes-
tine, which may trigger specific NSAID-related pathogenic
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mechanisms in the distal GI tract [137]. Some recent
experimental evidence [138] suggests that PPIs might
actually worsen the NSAID intestinal damage by indu-
cing dysbiosis, an adverse event repeatedly described in
humans [139,140].
Like non-selective compounds, COX-2 selective NSAIDs
damage the small bowel, but the frequency and severity of
events are generally lower. Indeed, a systematic review
found that COX-2 selective inhibitors had significantly
less effect versus ns-NSAIDs in 3/4 GI integrity studies,
one endoscopic study (RR mucosal breaks, 0.3), and two
randomized studies (RR lower GI clinical events, 0.5;
hematochezia, 0.4) [131]. The better intestinal tolerability
of the selective agent, celecoxib, persisted even when the
ns-NSAID was combined with a PPI [135,136]. In ad-
dition, switching RA patients on long-term ns-NSAIDs to
celecoxib resulted in a significant reduction of small bowel
injury [141]. While two large outcome studies (the VIGOR
and CONDOR trials) showed a reduced risk of more
serious events in the lower or the whole GI tract, for
rofecoxib and celecoxib, respectively [108,130], this be-
nefit was not confirmed for etoricoxib in the Multina-
tional Etoricoxib versus Diclofenac Arthritis Long-term
(MEDAL) program [142].
The impact of upper GI tract adverse effects can be
mitigated by the use of PPIs. The lack of efficacy of these
agents in preventing lower GI tract damage is however
an unmet clinical need that requires addressing. The use
of non acidic COX-2 selective inhibitors, such as cele-
coxib, may help to reduce the risk of damage throughout
the entire GI tract, but much work is needed to define the
best preventive strategy for the lower GI tract in NSAID
users.
Statement 6: Celecoxib is associated with fewer ad-
verse events throughout the entire GI tract compared to
ns-NSAIDs. Level of Agreement: Strong Agreement
(vote statement: a, 62.5%; b, 18.8%; c, 18.8%). Level of
Evidence: A (vote grade: A, 46.9%; B, 43.8%; C, 9.4%).
A meta-analysis of RCTs showed that COX-2 selective
inhibitors were associated with significantly fewer gastro-
duodenal ulcers (RR, 0.26; 95% CI, 0.23–0.30) and cli-
nically important ulcer complications (RR, 0.39; 95% CI,
0.31–0.50) than ns-NSAIDs [143]. Other studies have also
shown that celecoxib is as safe to the upper GI tract as
ns-NSAIDs plus a PPI [144].
It is now well known that NSAIDs induce mucosal
damage to the small and large bowel, including inflam-
mation, erosions, ulcers, bleeding, perforation, and ob-
struction [61,145]. Epidemiological studies have reported
an increased risk of lower GI bleeding and perforation
with NSAID and aspirin use [146,147]. More recently,
biochemical and endoscopy capsule studies have shown
a high frequency of mucosal inflammation and mucosal
breaks in both healthy subjects [133] and patients
taking NSAIDs [132]. Although PPIs are increasingly
used to prevent NSAID-related GI adverse events, they
do not protect from lesions beyond the duodenum (see
Statement 5). This may explain the increasing number
of hospitalizations due to complications of the lower GI
tract, seen in some studies, whereas the corresponding
numbers for upper GI complications are decreasing (see
Statement 4) [41].
Capsule endoscopy studies [135,136] have demon-
strated that, compared to ns-NSAIDs plus a PPI, cele-
coxib alone was associated with less mucosal damage of
the small bowel in healthy volunteers. In the 6-month,
double-blind, randomized CONDOR trial, in patients
with OA or RA at increased GI risk [108], fewer (0.9%)
subjects receiving celecoxib (200 mg b.i.d) met the cri-
teria for the primary endpoint (clinically significant up-
per and lower GI events) compared to those receiving
diclofenac (75 mg b.i.d.) plus omeprazole (3.8%; hazard
ratio [HR] = 4.3; 95% CI, 2.6–7.0). Also, fewer patients
taking celecoxib withdrew early because of GI adverse
events compared to patients taking diclofenac plus ome-
prazole. Most of the outcome events were a drop in
hemoglobin ≥2 g/dL attributed to identified lesions from
the upper GI tract or to presumed small bowel lesions.
These data have been confirmed in a recent 6-month ran-
domized, open-label, blinded endpoint study that measured
clinical outcomes throughout the GI tract [148]. Celecoxib
use was associated with a lower risk of clinically significant
upper and lower GI events than ns-NSAIDs (OR, 1.82;
95% CI, 1.31–2.55) [148]. However, a recent epidemio-
logical study carried out in Taiwan has shown celecoxib to
be associated with an increased risk of complications in the
lower GI tract, similar to other NSAIDs [149]. These data
need to be confirmed, since epidemiological studies are in-
evitably associated with different biases and confounding
factors that may be difficult to control.
A relevant question is whether data on the safety of cel-
ecoxib in the lower GI tract can be extrapolated to other
COX-2 selective inhibitors, since NSAID-associated mu-
cosal damage in the lower GI tract depends not only on
COX-1/COX-2 inhibition, but also on the physicochemi-
cal properties and the entero-hepatic circulation of indi-
vidual NSAIDs [30].
In a 28-day trial conducted in healthy volunteers, Hunt
et al. [150] found that fecal blood loss with etoricoxib
(120 mg o.d.) was similar to placebo and significantly
lower than that found in patients treated with ibuprofen
(800 mg t.d.s.). However, the MEDAL program [142] did
not confirm a decrease in lower GI complications with
etoricoxib versus diclofenac.
Statement 7: The combination of celecoxib plus low-dose
aspirin is associated with a lower risk of adverse events in
the upper GI tract, as compared with ns-NSAIDs plus
low-dose aspirin. Level of Agreement: Strong Agreement
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(vote statement: a, 43.8%; b, 28.1%; c, 6.3%; d, 9.4%; e, 3.1%;
f, 9.4%). Level of Evidence: B (vote grade: A, 25.0%; B,
40.6%; C, 25.0%; D, 3.1%; E, 6.3%).
It is well established that low-dose aspirin exerts a life-
saving antithrombotic effect, particularly in secondary
prevention [151]. However, a large cohort study [121]
and a meta-analysis of 35 RCTs, including 87,581 pa-
tients [122], have clearly shown that its use is associated
with an increased risk of GI bleeding. This risk is further
increased when aspirin is combined with clopidogrel or
anticoagulants [122] and appears to be independent of
the formulation of aspirin used (e.g., buffered or enteric
coated) [152].
The well-known risk of upper GI events associated
with the use of ns-NSAIDs is significantly enhanced by
concomitant use of low-dose aspirin, a quite frequent
clinical situation in older patients having both OA and
CV co-morbidities [153,154]. A large, hospital-based,
case-control study, performed in Spain, found that add-
ing low-dose aspirin to ns-NSAIDs, increased the risk of
upper GI bleeding by more than two-fold [155]. Similarly,
a Canadian retrospective cohort study found a 62% in-
crease in hazard ratio of hospitalization for GI events in
patients taking these combinations, although the combin-
ation of celecoxib with low-dose aspirin was associated
with a lower risk (HR, 0.62; 95% CI, 0.48–0.80) than the
association of ns-NSAIDs plus low-dose aspirin [156].
When COX-2 selective inhibitors were examined as
a class, conflicting results were reported by different
studies. In the case of three epidemiological studies, one
(a hospital-based, case-control) found a similar RR of
upper GI bleeding when low-dose aspirin was combined
with COX-2 selective inhibitors or ns-NSAIDs [155],
while the others (nested case-control studies, performed
in databases from the UK) observed an increased RR of
upper GI complications when ns-NSAIDs or COX-2 se-
lective agents were used together with an antiplatelet
agent [157,158]. However, in a meta-analysis of four
RCTs including 17,276 patients, the RR for perforation,
ulcer, and bleeding between the combination low-dose
aspirin/COX-2 selective inhibitors and low-dose aspirin/
ns-NSAIDs was 0.72 (95% CI, 0.62–0.95) [143]. However,
these were post hoc analyses and not randomised compari-
sons, which suggest a possible bias by patient selection.
As expected, the analysis of the risk associated with
the combination of low-dose aspirin with individual
COX-2 selective inhibitors also yielded different results.
Indeed, with the exception of the Celecoxib Long-Term
Arthritis Safety Study (CLASS) trial (where high doses,
i.e., 800 mg/day, of the drug were employed) [159], all
the available studies (be they epidemiological or RCTs)
[156,160-162], as well as a meta-analysis of 31 RCTs
(n = 39,605) [163], point to a lower upper GI risk of low-
dose aspirin in combination with celecoxib than with the
same antiplatelet agent combined with an ns-NSAID.
However, it must be clear that low-dose aspirin potenti-
ates the GI risk of either a selective COX-2 inhibitor or
ns-NSAID and that, in patients with high GI risk, these
combinations may still be harmful and gastroprotection
with a PPI seems appropriate and beneficial [31].
In contrast, in the MEDAL program, the pre-specified
pooled intent-to-treat analysis of the three RCTs (i.e.,
Etoricoxib versus Diclofenac sodium Gastrointestinal tol-
erability and Effectiveness trial (EDGE)-I, EDGE-II, and
MEDAL), comparing etoricoxib with diclofenac in an
overall population of 11,418 OA/RA patients taking low-
dose aspirin the HR for overall upper GI clinical events
was 0.78 (95% CI, 0.60–1.1), indicating a lack of significant
difference between the two anti-inflammatory drugs [164].
Consistent with this finding, the cumulative rate of patient
discontinuation due to clinical and laboratory upper GI
adverse events was also not statistically different in the
two treatment arms [165]. No formal studies have evalu-
ated the GI risk of dual antiplatelet therapy in patients tak-
ing either ns-NSAIDs or coxibs.
Recent video capsule studies have shown that low-dose
aspirin is also harmful to the small intestine [166-168].
The combination of aspirin with ns-NSAIDs would likely
be more damaging. However, studies providing such evi-
dence are lacking and, more importantly, the clinical rele-
vance of these mucosal lesions need to be defined in the
context of serious and life-threatening outcomes such as
bleeding and perforation.
CV risk of NSAIDs
Statement 8: The risk of CV events associated with cele-
coxib use is similar to that associated with the use of
most ns-NSAIDs. Level of Evidence: Strong Agreement
(vote statement: a, 68.8%; b, 15.6%; c, 9.4%; d, 6.3). Level
of Evidence: A (vote grade: A, 53.1%; B, 40.6%; C, 6.3%).
Although OA is not apparently an independent risk
factor for CV disease, many OA patients are elderly and
concomitant CV disease is not uncommon. In a nested
case-control study (n ≥1,400,000) by Graham et al. [169],
an increased CV risk was associated with rofecoxib as well
as ns-NSAIDs. In RCTs, rofecoxib demonstrated a higher
incidence of CV adverse events than naproxen in non-
aspirin users with RA [109] or than placebo in patients
with colorectal adenomas (Adenomatous Polyp Preven-
tion on Vioxx™ (APPROVe) trial) [170]. For celecoxib, an
increase in CV events was noted in patients with colorec-
tal cancer when compared with placebo [171]. However, in
these trials, the absolute numbers were low. In a RCT in
Alzheimer’s disease, CV events were higher with naproxen
compared to celecoxib or placebo [172]. In the CLASS
study performed in OA and RA patients, there was no dif-
ference in CV events between celecoxib (400 mg b.i.d.)
and ns-NSAIDs [173]. In the MEDAL trials, etoricoxib
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showed a similar cumulative incidence of thrombotic CV
events to diclofenac [106]. A large meta-analysis of cohort
and nested case-control studies also found an increased
risk of CV events for all ns-NSAIDs and COX-2 selective
inhibitors [46]. Other meta-analyses concluded that COX-
2 selective agents and ns-NSAIDs have similar CV risk
[47,174,175]. A recent network meta-analysis, which
aimed to compare the CV risk of ns-NSAIDs and COX-2
selective inhibitors, found a similar CV risk between these
two classes of anti-inflammatory compounds [48]. Na-
proxen appeared to be the least harmful, but this advan-
tage has to be weighed against GI toxicity. It also must be
considered that the absence of an increased CV risk ob-
served in RCTs and meta-analysis with naproxen, when
compared to placebo, was based on a high naproxen dose
(500 mg b.i.d) [47].
Putting the CV risk in OA patients into context, the
incidence of the GI risk is higher than the CV risk, and
COX-2 selective inhibitors have a lower GI risk than
ns-NSAIDs. Taking all the available data from clinical
trials, meta-analyses, and cohort studies into account,
the overall CV risk is increased for both ns-NSAIDs and
COX-2 selective inhibitors. For each COX-2 selective
inhibitor, however, the reduction of complicated upper
GI events was numerically greater than any increase in
Antiplatelet Trialists’ Collaboration events (fatal or non-
fatal myocardial infarction or stroke, or vascular death)
[176]. There is no evidence of major differences between
ns-NSAIDs and COX-2 selective inhibitors. Hitherto,
there is no published RCT which has been specifically
designed to compare CV risk between ns-NSAIDs and
COX-2 selective inhibitors. Results of the Prospective
Randomized Evaluation of Celecoxib Integrated Safety
versus Ibuprofen or Naproxen (PRECISION) study will
provide important data on the comparative CV safety of
celecoxib, ibuprofen, and naproxen. It is worthwhile men-
tioning that this trial, performed in a high CV risk popula-
tion, is the first study specifically designed to assess the
CV safety of anti-inflammatory drugs [177]. Unfortunately,
the trial has been delayed because of slow enrollment and
full results are not expected until 2016 [178].
Statement 9: COX-2 selective inhibitors do not in-
terfere with the antiplatelet effect of low-dose aspirin.
Level of Agreement: Strong Agreement (vote statement:
a, 65.6%; b, 21.9%; c, 6.3%; d, 6.3%). Level of Evidence: A
(vote grade: A, 77.4%; B, 16.1; C, 3.2%; D, 3.2%).
The benefits of low-dose aspirin use in secondary pre-
vention clearly outweigh the risk [151]. However, this is
not the case for primary prevention [179], where recom-
mendations for aspirin use should be individualized, tak-
ing into account the balance between benefits and risks,
as well as individual patient values and preferences [180].
Given that aspirin is a life-saving drug, discontinuing it
or not adhering to the correct administration schedule
enhances the risk of CV and cerebral events by more
than three-fold [181,182]. This risk was magnified by up
to 90-fold in patients with intracoronary stents [182].
Ns-NSAIDs, being COX-1-inhibitors, all impair throm-
boxane A2 synthesis and, as a consequence, platelet aggre-
gation, although the magnitude and duration of this effect
varies amongst the different compounds [183]. With the
exception of diclofenac [184,185] and meloxicam [186], al-
most all ns-NSAIDs can interfere with the anti-aggregant
effect of aspirin [185,187-189].
While the pharmacodynamic, negative interaction be-
tween ns-NSAIDs and low-dose aspirin has been clearly
established by studies in healthy volunteers and patients,
the clinical consequences of such interaction are still not
definitely ascertained. Indeed, available epidemiological
studies provided conflicting results, with only three out of
six reports showing a reduction of the cardio-protective
effect of aspirin [190-195]. However, the few RCTs avail-
able are consistent in their findings that ns-NSAID use
does worsen the CV outcome in patients taking low-dose
aspirin. Indeed, in the Physicians’ Health Study, the regu-
lar use of these agents was associated with an increased
risk (RR, 2.86; 95% CI, 1.25–6.56) of acute recurrent
myocardial infarction [196]. Similarly, in the Therapeu-
tic Arthritis Research and Gastrointestinal Event Trial
(TARGET), designed to assess the GI and CV safety of
lumiracoxib versus naproxen and ibuprofen, a post hoc
subgroup analysis of high CV risk patients (n = 3,042)
taking low-dose aspirin (60%) found a higher CV event
rate in ibuprofen users compared to lumiracoxib users
(1.48 versus 0.85 events per 100 patient/years) [197].
Besides the CV harm, concomitant administration of
ns-NSAIDs and low-dose aspirin can be followed by
stroke recurrence in patients with prior cerebrovascular
events [188].
COX-2 selective NSAIDs spare platelet COX-1 activity
[198] and do not affect platelet aggregation [184,198-201]
or bleeding time [200]. Similarly, COX-2 selective inhi-
bitors do not interfere with the anti-aggregant activity of
low-dose aspirin both in healthy subjects [184,186,187,198]
and patients with coronary heart disease [202,203]. Con-
sistent with these results, in vitro studies on human plate-
lets have shown that a low affinity for COX-1 and a high
degree of COX-2 selectivity confers a low potential to
block aspirin inhibition of platelet COX-1 [204].
Taking all the above lines of evidence into account,
COX-2 selective inhibitors should represent the anti-
inflammatory drugs of choice for patients taking low-
dose aspirin for CV or cerebrovascular prevention [205],
provided the anti-inflammatory therapy is deemed neces-
sary and cannot be avoided with alternative therapies. It
should be emphasized, however, that the European Medi-
cines Agency’s (EMA) Committee for Medicinal Products
for Human Use stated - in 2005 - that “COX-2 inhibitors
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must not be used in patients with established ischemic
heart disease and/or cerebrovascular disease (stroke)”
[206]. Therefore, the benefits (i.e., lack of blunting of as-
pirin protection and the anti-inflammatory/analgesic
activity) should be balanced against the possible CV
risks, which ultimately depend on individual patients’
clinical characteristics and co-medications.
Discussion
Current guidelines on NSAID use have been developed by
rheumatologists [60,65], gastroenterologists [57-59,61],
cardiologists [64,70], or multidisciplinary teams of experts
[62,63,66,68,69]. Rheumatologists were first concerned
with safety, thus recommending paracetamol (acetamino-
phen) as a first-line analgesic. Gastroenterologists dealt
mainly with GI risk factors and gastroprotection, em-
phasizing how misused and underused it is, while cardi-
ologists were worried about CV safety and suggested
naproxen use in patients with CV risk factors. Some mul-
tidisciplinary consensus papers discussed both GI and CV
risks and put forward evidence-based proposals on how to
balance the benefits and risks of anti-inflammatory ther-
apy [66,68,69]. Despite this, some important issues have
been left unsettled, partly because sufficient evidence was
not available at the time of guideline drafting.
Navigating through the different GI and CV risk fac-
tors and balancing them with the potential benefits of
NSAID therapy is a difficult task. This is why a team of
34 experts, from five different disciplines, gathered to-
gether to critically examine and grade the current evi-
dence with the aim of achieving a consensus on how to
best manage complex patients with high GI and/or CV
risks. The Consensus statements and their comparison
with those of previous guidelines [8,26,27,64,66-68,32]
are summarized in Table 2.
On the basis of this consensus, before starting anti-
inflammatory therapy, the real need for it should be
carefully assessed and the CV risks (that are not easily
modifiable) as well as upper and lower GI risk factors
should be quantified. Until now, the evaluation of lower
GI risk has been hampered by the lack of knowledge of
the corresponding risk factors, which – conversely from
those related to upper GI complications – are still poorly
understood. Analysis of the data from the MEDAL pro-
gram (i.e., MEDAL, EDGE-I, and EDGE-II studies) has
shown that the risk of a lower GI clinical event with
NSAID use seems to be constant over time, and the major
risk factors are a prior lower GI event and older age [142].
Colonic diverticula were the most common cause of blee-
ding in this study, confirming that NSAIDs are independ-
ent risk factors for colonic diverticular hemorrhage [207].
Old age (≥65 years) and a recent event were also found
to be significant risk factors in epidemiological studies
[141,155], which also demonstrated that an increased
number of co-morbidities represent an additional risk
factor for lower GI complications. In a cross-sectional
video capsule study, performed in RA patients under
NSAID treatment for more than 3 months, elderly pa-
tients and users of acid suppressants (H2-receptor an-
tagonists and PPIs) were more likely to develop severe
enteropathy [208]. A recent post hoc analysis of the
CONDOR trial [209] showed that baseline C-reactive
protein levels, history of gastritis and of GI intolerance,
H. pylori infection, old age, and body mass index were
all associated with clinically significant blood loss in
OA patients treated with NSAIDs.
The better upper GI safety of COX-2 selective agents
over ns-NSAIDs is well established [150,163,210-212].
However, their individual lower GI tolerability is less
well evidenced and appears to differ. Indeed, while the
serious lower GI events with rofecoxib (withdrawn from
the market) were significantly reduced in comparison
with ns-NSAIDs [130], this was not the case for etori-
coxib [142]. Likewise, the CONDOR trial [108], by using
the novel composite score of clinically significant upper
and lower GI events [213], has shown that celecoxib has
a better GI safety in the entire GI tract compared to
diclofenac plus omeprazole, a finding confirmed by the
recent GI-REASONS trial in the real world setting [148].
A recent meta-analysis of 51,000 patients enrolled in 52
RCTs from the celecoxib clinical database showed that,
when compared with ns-NSAIDs, celecoxib is associated
with a significantly lower risk of all clinically significant
GI events throughout the entire GI tract [214]. This su-
perior lower GI tolerability in patients is backed by video
capsule studies in healthy volunteers [135,136] and RA
patients, where the number and severity of intestinal le-
sions during ns-NSAID therapy were significantly re-
duced after switching to celecoxib [141].
Being a COX-2 selective agent, celecoxib displays the
same overall CV risk of ns-NSAIDs [45-48]. This was
confirmed by a recent meta-analysis of individual par-
ticipant data from RCTs [215]. This study showed that
the vascular risks of high-dose diclofenac, and possibly
ibuprofen, are comparable to selective COX-2 agents,
whereas high-dose naproxen is associated with less vas-
cular risk than other NSAIDs. This conclusion, how-
ever, should be viewed with caution since it was based
on non-randomized and indirect comparison between
the different compounds. As a consequence, the US Food
and Drug Administration Advisory Panel recently felt
that the evidence of CV safety is not conclusive enough
to warrant a label change, especially pending the re-
sults of the PRECISION study [216]. Interestingly, direct
comparison of celecoxib (both 200 and 400 mg) with
naproxen did not show any difference in CV risk while
both rofecoxib and etoricoxib displayed an increased
risk [215].
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Table 2 Comparison between the statements of this expert consensus with related statements issued by different guidelines
Statement of this
expert consensus
EULAR guidelines
(2005) [26]
Joint ACCF/ACG/AHA
and AHA guidelines
(2007–2008) [64,66]
OARSI guidelines
(2008) [27]
ACR guidelines
(2008) [8]
Intl working party
(2008) [67]
Canadian consensus
(2009) [68]
ACG guidelines
(2009) [32]
1 OA impacts quality
and quantity of life;
it should therefore
be treated
appropriately
No statement No statements The optimal
management of OA
requires a combination
of non-
pharmacological and
pharmacological
treatment modalities
No statement No statement No statement No statement
2 Many OA patients
requiring NSAID
therapy are not
being treated
appropriately
according to their
GI risk profile
No statement No statements No statement No statement No statement No statement No statement
3a The efficacy of
ns-NSAIDs and
COX-2 selective
inhibitors in pain is
comparable in
patients with OA
NSAIDs, at the lowest
effective dose, should
be added or
substituted in patients
who respond
inadequately to
paracetamol
No statements No statement Selective and
ns-NSAIDs have
comparable efficacy in
treating pain and
improving function in
the treatment of OA
and RA pain
No statement In general, ns-NSAIDs
have similar
effectiveness in
improving pain and
function in patients
with arthritis
No statement
3b The efficacy of
ns-NSAIDs and
COX-2 selective
inhibitors in pain is
comparable in
patients with RA
See above No statements No statement See above No statement COX-2 inhibitors are
as effective as
ns-NSAIDs in improving
pain and function in
patients with arthritis
No statement
4 NSAID use is
associated with
increased risk of
adverse events
throughout the
entire GI tract; this is
associated with
substantial mortality
In patients with
increased GI risk,
ns-NSAIDs plus a
gastroprotective agent,
or a selective COX-2
inhibitor (coxib) should
be used
No specific statements,
but the guidelines
assume that NSAIDs
increase the risk of
upper GI complications
In patients with
symptomatic hip or
knee OA, NSAIDs
should be used at the
lowest effective dose,
but their long-term
use should be avoided
if possible
NSAIDs are associated
with GI adverse events,
including peptic ulcer
disease, gastritis,
esophagitis, and their
complications
No specific statement,
but the document
assumes that NSAIDs
increase the risk of
upper GI complications
Aspirin and ns-NSAIDs
increase the risk of
upper GI complica-
tions. Aspirin and ns-
NSAIDs increase the
risk of small and large
bowel bleeding and
other complications
Patients requiring
NSAID therapy who
are at high risk (e.g.,
prior ulcer bleeding
or multiple GI risk
factors) should receive
alternative therapy, or
if anti-inflammatory
treatment is abso-
lutely necessary, a
COX-2 inhibitor, and
co-therapy with
misoprostol or high-
dose PPI
Scarpignato
et
al.BM
C
M
edicine
 (2015) 13:55 
Page
12
of
22
Table 2 Comparison between the statements of this expert consensus with related statements issued by different guidelines (Continued)
5 NSAID-induced
adverse events in the
lower GI tract are
not prevented by
PPIs
In patients with
increased GI risk,
ns-NSAIDs plus a
gastroprotective agent,
or a selective COX-2
inhibitor (coxib) should
be used
PPIs are the preferred
agents for the therapy
and prophylaxis of
NSAID- and aspirin-
associated GI injury
In patients with
increased GI risk, either
a COX-2 selective
agent or a ns-NSAID
with coprescription of
a PPI or misoprostol
for gastroprotection
may be considered
If a patient and
provider agree to
utilize an NSAID for
arthritis pain relief, and
the patient has risk
factors for GI bleeding,
then the patient
should be treated
concomitantly with
either misoprostol or a
PPI
No specific statement
and no mention of the
lower GI tract
PPI therapy reduces
the risk of ns-NSAID
associated endoscopic
ulcer disease, but there
is less evidence for a
reduction in bleeding
events. In patients with
prior GI bleeding, the
combination of a PPI
and a COX-2 inhibitor
reduces the risk of
upper GI bleeding
from that of COX-2
inhibitors alone
No statement
6 Celecoxib is
associated with
fewer adverse events
throughout the
entire GI tract
compared to
ns-NSAIDs
In patients with
increased GI risk,
ns-NSAIDs plus a
gastroprotective agent,
or a selective COX-2
inhibitor (coxib) should
be used
No specific statement,
but the guidelines
assume that coxibs are
safer than ns-NSAIDs
for the upper GI tract
In patients with
increased GI risk, either
a COX-2 selective
agent or a ns-NSAID
with coprescription of
a PPI or misoprostol
for gastroprotection
may be considered
No specific statement Coxibs considered
safer than ns-NSAIDs
to the upper GI tract
Compared to
ns-NSAIDs, COX-2
inhibitors are
associated with a
lower risk of upper GI
bleeding
COX-2 inhibitors are
associated with a
significantly lower
incidence of gastric
and duodenal ulcers
when compared to
traditional NSAIDs
7 The combination of
celecoxib plus low-
dose aspirin is
associated with a
lower risk of adverse
events in the upper
GI tract, as
compared with
ns-NSAIDs plus
low-dose aspirin.*
No statement As the use of any
NSAID, including COX-
2 selective agents and
over-the-counter doses
of traditional NSAIDs,
in conjunction with
low-dose aspirin,
substantially increases
the risk of ulcer
complications, a
gastroprotective
therapy should be
prescribed for at-risk
patients
No statement If a patient is taking
aspirin for
cardioprotective
benefit, then selective
and ns-NSAIDs should
be avoided
All patients should be
given a PPI if on
aspirin and taking
NSAIDs.
The risk of GI bleeding
is increased when
aspirin is co-prescribed
with ns-NSAIDs com-
pared to NSAIDs alone.
The risk of GI bleeding
is increased when as-
pirin is co-prescribed
with COX-2 inhibitors
compared with COX-2
inhibitors alone
The GI benefit of
COX-2 inhibitors is
negated when the
patient is taking
concomitant low-
dose aspirin.Naproxen
recommended as
NSAID of choice Patients for whom
anti-inflammatory
analgesics are
recommended, who
also require low-dose
aspirin therapy for CV
disease, can be
treated with naproxen
plus misoprostol or
a PPI
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Table 2 Comparison between the statements of this expert consensus with related statements issued by different guidelines (Continued)
8 The risk of CV events
associated with
celecoxib use is
similar to that
associated with the
use of most
ns-NSAIDs
No statement The AHA guidelines
assume that coxibs
carry the highest CV
risk and recommend
the use of naproxen as
the drug of choice for
patients with CV risk
NSAIDs, including both
non-selective and
COX-2 selective agents,
should be used with
caution in patients
with CV risk factors
Selective NSAIDs might
pose increased CV risk
compared with
ns-NSAIDs through
several potential
mechanisms. A
systematic review of
observational studies
suggests that celecoxib,
in commonly used
doses, does not
significantly increase CV
risk. It is likely that
higher doses,
particularly when
administered twice
daily, increase the
CV risk
Use of coxibs
considered
inappropriate; use of
naproxen considered
appropriate
COX-2 inhibitors
increase the risk of
coronary heart disease
events; non-naproxen
ns-NSAIDs increase
the risk of coronary
heart disease events;
naproxen is associated
with a lower risk of
coronary heart disease
events than other
ns-NSAIDs and COX-2
inhibitors
The lowest possible
dose of celecoxib
should be used in
order to minimize the
risk of CV events.
Patients at moderate
GI risk who also are at
high CV risk should
be treated with
naproxen plus
misoprostol or a PPI.
Patients at high GI
and high CV risk
should avoid using
NSAIDs or coxibs.
Alternative therapy
should be prescribed
9 COX-2 selective
inhibitors do not
interfere with the
antiplatelet effect of
low-dose aspirin
No statement Evidence indicates that
ibuprofen, but not
rofecoxib (a COX-2
inhibitor), interferes
with aspirin’s ability to
irreversibly inactivate
COX-1
No statement Selective NSAIDs do
not appear to have
relevant drug–drug
interactions with the
anticoagulant effect of
aspirin
No specific statement
or comment
No statement No statement
*This does not preclude the use of PPIs for gastroprotection. ACCF, American College of Cardiology Foundation; ACG, American College of Gastroenterology; ACR, American College of Rheumatology; AHA, American
Heart Association; CV, Cardiovascular; EULAR, European League Against Rheumatism; GI, Gastrointestinal; NSAIDs, Non-steroidal anti-inflammatory drugs; ns-NSAIDs, Non-selective NSAIDs; OA, Osteoarthritis; OARSI,
Osteoarthritis Research Society International; PPI, Proton pump inhibitors; RA, Rheumatoid Arthritis; RCT, Randomized clinical trial.
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A meta-analysis of RCTs in rheumatologic conditions
failed to show an increased CV risk associated with cele-
coxib compared to placebo [174], while a safety analysis
from six RCTs, performed in patients with conditions
other than arthritis, provided evidence of a differential
CV risk as a function of celecoxib dose, regimen, and
baseline CV risk [217]. The risk appeared to be non-
significant (HR, 1.1; 95% CI, 0.6–2.0) for the 400 mg q.d.
dose, intermediate for the 200 mg b.i.d. dose (HR, 1.8;
95% CI, 1.1–3.1), and high for the 400 mg b.i.d. dose
(HR, 3.1; 95% CI, 1.5–6.1) [217]. The recent Coxib and
traditional NSAID Trialists meta-analysis [215] also found
a trend towards less risk with lower celecoxib doses. In-
deed, the vascular effects of celecoxib 200 mg daily (the
most widely used regimen) were statistically uncertain.
In contrast to ns-NSAIDs, celecoxib does not impair
the antiplatelet activity of low-dose aspirin, either alone
[187,202] or in combination with clopidogrel [203]. This
lack of interference with the antithrombotic action of anti-
platelet drugs would make this COX-2 selective agent a
suitable anti-inflammatory drug for patients receiving
low-dose aspirin for CV or cerebrovascular prevention
[205], despite the contrary opinion of the EMA [206].
However, at the time when the Committee for Medicinal
Products for Human Use issued its recommendations,
much of the current evidence was not yet available. Al-
though no specific data are available, the present recom-
mendations should be valid for patients either on single or
dual antiplatelet therapy.
Epidemiological studies have shown that the presence
of co-morbidities increases both the GI [218] and CV
[219] risk, which are not stable. Previous GI bleeding
(recent or remote) put NSAID users at high risk of re-
bleeding. NSAID treatment should therefore be avoided
but – if mandatory – after H. pylori eradication in infected
patients, celecoxib plus a PPI are the best evidence-based
therapeutic option [31]. Although no current guideline
suggests an option for lower GI bleeding, the better upper
and lower GI tolerability of celecoxib outlined above does
suggest its combination with a PPI is the best strategy for
prevention of both upper and lower GI bleeding in high
risk patients.
Along the same lines, elevated CV risk is most prom-
inent soon after acute myocardial infarction (AMI), al-
though risk declines with time [220]. Although NSAIDs
are contraindicated among patients with established CV
disease, many receive NSAID treatment for a short period
of time. Even short-term treatment with most NSAIDs
has been associated with increased risk of death and re-
current AMI in patients with prior AMI [221]. How-
ever, no increased risk was observed for celecoxib users
in a population-based cohort of Canadian patients aged
66 years and older, who survived hospitalization for
AMI [222]. Therefore, even in patients with high CV risk,
celecoxib appears to be the least harmful NSAID, espe-
cially since patients will be on low-dose aspirin therapy.
Taking into account the risk/benefit ratio of the available
COX-2 selective inhibitors and ns-NSAIDs, celecoxib at
lowest approved dose (200 mg once daily, hereinafter re-
ferred to as low-dose) appears to be the safest option in
patients with concomitant high GI (both upper and/or
lower) and CV risks, if NSAIDs are necessary and the pa-
tient is on low-dose aspirin. Figure 1 suggests an algo-
rithm for the use of long-term NSAID therapy according
Figure 1 Algorithm for long-term NSAID therapy according to a patient’s GI and CV risk factors.
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to individual GI and CV risk. For patients with both low
GI and CV risks, any ns-NSAID alone may be accept-
able. For those with low GI and high CV risk, naproxen
may be preferred because of the potential lower CV risk
compared with other ns-NSAIDs or COX-2 selective
inhibitors. Taking into account the current evidence
[174,217-224], also low-dose (200 mg), once daily cele-
coxib may be acceptable. However, in those patients
who are on low-dose aspirin, naproxen would impair
the anti-aggregant activity of this antiplatelet agent.
This interaction is more evident when this NSAID is
given before aspirin than when it is given after [189].
COX-2 selective inhibitors, as a class, are therefore in-
dicated as anti-inflammatory agents [70,205], a choice also
recommended by the Canadian Cardiovascular Society
[70]. Low-dose celecoxib is the preferred agent because
of a better CV and GI profile.
In patients with high GI risk, testing for and eradica-
ting H. pylori should be considered [33,34,68], but will
be insufficient without ongoing gastroprotection. In these
patients, if CV risk is low, a COX-2 selective inhibitor
alone or ns-NSAID with a PPI appear to offer similar pro-
tection from upper GI events. However, according to re-
cent evidence, only celecoxib will reduce mucosal harm
throughout the entire (upper and lower) GI tract. This
agent should be combined with a PPI in patients at very
high risk of upper GI bleeding [31]. When both GI and
CV risks are high, the optimal strategy is to avoid NSAID
therapy, if at all possible. If the NSAID therapy is deemed
necessary, the therapeutic approach will depend on co-
medication. If the patient is not on antiplatelet therapy
(because, for instance, the benefits of primary prevention
have been considered not to outweigh the risks [179]),
either naproxen or low-dose celecoxib could be con-
sidered, but should be combined with a PPI, while this
COX-2 selective agent seems the most appropriate choice
in patients on low-dose aspirin. It should be emphasized
that the suggested algorithm should be viewed as a
“general guidance”, which needs to be tailored to the
individual patient, taking into account co-morbidities
and co-therapies.
Besides efficacy and safety, costs will also influence
therapeutic choices. However, together with medication
costs, the economic burden on the healthcare system of
NSAID-induced GI or CV events should be taken into
account. Prior to the 2008 National Institute for Health
and Clinical Excellence (NICE) clinical guideline for the
management of OA [225], a number of economic evalu-
ations of COX-2 inhibitors and NSAIDs had been com-
pleted, but none included the full range of important
adverse events. While most included GI adverse events,
none included all of the relevant CV events [226]. The
2008 NICE clinical guideline for OA included an update
[227] of their 2001 technology appraisal of COX-2
selective inhibitors and NSAIDs [228]. For the guideline,
the economic model was updated to include new avail-
able evidence from the CONDOR study. The analysis
found that adding a PPI to an ns-NSAID or a COX-2 se-
lective inhibitor was a cost-effective treatment strategy
[227,229]. This was the case for patients at relatively
low GI risk, as well as for those at high risk. When the
CONDOR study became available, the model was adap-
ted to include relative risks of adverse events concern-
ing the lower GI tract [230]. The results of the analysis
showed that celecoxib plus a PPI remains a cost-effective
strategy for the treatment of OA compared to diclofenac
plus a PPI; this is an important new message for clinicians.
Indeed, previous guidance recommended that adding a
PPI to an ns-NSAID or prescribing a COX-2 inhibitor
should only be considered for patients at high risk of GI
adverse events, and that use of a PPI in addition to a
COX-2 inhibitor would not be cost effective, even for
high-risk patients [228].
Conclusions
NSAIDs are an essential part of our therapeutic arma-
mentarium despite their well characterized GI and CV
risk profiles. The time is now ripe for offering the patient
with OA the safest and most cost-effective therapeutic op-
tion, thus preventing serious adverse events, which could
have important QoL and resource use implications. The
integration of existing guidelines with the present one, to-
gether with a careful evaluation of both GI and CV risk
factors, should allow clinicians to correctly manage OA
patients without expanding the already growing NSAID
epidemic. In the future, the potential chemopreventive ef-
fects of NSAIDs/coxibs [231,232] and of low-dose aspirin
[233,234] on GI (as well as non-GI) cancers may impact
the benefits and risks equation, observed in the arthritic
population, and expand the use of these compounds.
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